-
1
-
-
0026099498
-
Interaction of citrus juices with felodipine and nifedipine
-
Bailey DG, Spence JD, Munoz, C., Arnold JM Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991 ; 337: 268-269.
-
(1991)
Lancet
, vol.337
, pp. 268-269
-
-
Bailey, D.G.1
Spence, J.D.2
Munoz, C.3
Arnold, J.M.4
-
2
-
-
0025952282
-
Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans
-
Soons PA, Vogels BA, Roosemalen MC, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991 ; 50: 394-403.
-
(1991)
Clin Pharmacol Ther
, vol.50
, pp. 394-403
-
-
Soons, P.A.1
Vogels, B.A.2
Roosemalen, M.C.3
-
3
-
-
3142523464
-
Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin
-
Lilja JJ, Neuvonen M., Neuvonen PJ Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol. 2004 ; 58: 56-60.
-
(2004)
Br J Clin Pharmacol
, vol.58
, pp. 56-60
-
-
Lilja, J.J.1
Neuvonen, M.2
Neuvonen, P.J.3
-
4
-
-
0031954328
-
Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid
-
Kantola T., Kivisto KT, Neuvonen PJ Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1998 ; 63: 397-402.
-
(1998)
Clin Pharmacol Ther
, vol.63
, pp. 397-402
-
-
Kantola, T.1
Kivisto, K.T.2
Neuvonen, P.J.3
-
5
-
-
0027363392
-
Trough concentration of cyclosporine in blood following administration with grapefruit juice
-
Ducharme MP, Provenzane R., Dehoorne-Smith M., Edwards DJ Trough concentration of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol. 1993 ; 36: 457-459.
-
(1993)
Br J Clin Pharmacol
, vol.36
, pp. 457-459
-
-
Ducharme, M.P.1
Provenzane, R.2
Dehoorne-Smith, M.3
Edwards, D.J.4
-
6
-
-
0029055363
-
Disposition of intravenous and oral cyclosporine after administration with grapefruit juice
-
Ducharme MP, Warbasse LH, Edwards DJ Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995 ; 57: 485-491.
-
(1995)
Clin Pharmacol Ther
, vol.57
, pp. 485-491
-
-
Ducharme, M.P.1
Warbasse, L.H.2
Edwards, D.J.3
-
7
-
-
0030982634
-
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
-
Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997 ; 99: 2545-2553.
-
(1997)
J Clin Invest
, vol.99
, pp. 2545-2553
-
-
Lown, K.S.1
Bailey, D.G.2
Fontana, R.J.3
-
8
-
-
0342868292
-
Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity
-
Guo LQ, Fukuda K., Ohta T., Yamazoe Y. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos. 2000 ; 28: 766-771.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 766-771
-
-
Guo, L.Q.1
Fukuda, K.2
Ohta, T.3
Yamazoe, Y.4
-
9
-
-
0033976593
-
Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model
-
Takanage H., Ohnishi A., Matsuo H., et al. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol. 2000 ; 49: 49-58.
-
(2000)
Br J Clin Pharmacol
, vol.49
, pp. 49-58
-
-
Takanage, H.1
Ohnishi, A.2
Matsuo, H.3
-
10
-
-
0030696487
-
Mechanisms of enhanced oral bioavailability of CYP3A4 substrates by grapefruit constitutes: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins
-
Schmiedlin-Ren P., Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral bioavailability of CYP3A4 substrates by grapefruit constitutes: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos. 1997 ; 25: 1228-1233.
-
(1997)
Drug Metab Dispos
, vol.25
, pp. 1228-1233
-
-
Schmiedlin-Ren, P.1
Edwards, D.J.2
Fitzsimmons, M.E.3
-
11
-
-
0035108539
-
Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol
-
Spahn-Langguth H., Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci. 2001 ; 12: 361-367.
-
(2001)
Eur J Pharm Sci
, vol.12
, pp. 361-367
-
-
Spahn-Langguth, H.1
Langguth, P.2
-
12
-
-
0036288273
-
Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates
-
Tian R., Koyabu N., Takanaga H., Matsuo H., Ohtani H., Sawada Y. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res. 2002 ; 19: 801-809.
-
(2002)
Pharm Res
, vol.19
, pp. 801-809
-
-
Tian, R.1
Koyabu, N.2
Takanaga, H.3
Matsuo, H.4
Ohtani, H.5
Sawada, Y.6
-
13
-
-
0036159433
-
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine
-
Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002 ; 71: 11-20.
-
(2002)
Clin Pharmacol Ther
, vol.71
, pp. 11-20
-
-
Dresser, G.K.1
Bailey, D.G.2
Leake, B.F.3
-
14
-
-
15344340313
-
Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B
-
Satoh H., Yamashita F., Tsujimoto M., et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005 ; 33: 518-523.
-
(2005)
Drug Metab Dispos
, vol.33
, pp. 518-523
-
-
Satoh, H.1
Yamashita, F.2
Tsujimoto, M.3
-
15
-
-
33947420519
-
Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice
-
Bailey DG, Dresser GK, Leake BF, Kim RB Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther. 2007 ; 81: 495-502.
-
(2007)
Clin Pharmacol Ther
, vol.81
, pp. 495-502
-
-
Bailey, D.G.1
Dresser, G.K.2
Leake, B.F.3
Kim, R.B.4
-
17
-
-
33745114173
-
AMN107 (nilotinib) a novel and selective inhibitor of BCR-ABL
-
Weisberg E., Manley P., Mestan J., Cowan-Jacob S., Ray A., Griffin JD AMN107 (nilotinib) a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006 ; 94: 1765-1769.
-
(2006)
Br J Cancer
, vol.94
, pp. 1765-1769
-
-
Weisberg, E.1
Manley, P.2
Mestan, J.3
Cowan-Jacob, S.4
Ray, A.5
Griffin, J.D.6
-
18
-
-
21144451094
-
Vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
-
OHare T., Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 205 ; 65: 4500-4505.
-
Cancer Res
, vol.205
, Issue.65
, pp. 4500-4505
-
-
Ohare, T.1
Walters, D.K.2
Stoffregen, E.P.3
-
19
-
-
13844251975
-
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
-
Weisberg E., Manley PW, Breitenstein W., et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005 ; 7: 129-141.
-
(2005)
Cancer Cell
, vol.7
, pp. 129-141
-
-
Weisberg, E.1
Manley, P.W.2
Breitenstein, W.3
-
20
-
-
33745086350
-
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
-
DOI 10.1056/NEJMoa055104
-
Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 ; 354: 2542-2551. (Pubitemid 43882350)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.24
, pp. 2542-2551
-
-
Kantarjian, H.1
Giles, F.2
Wunderle, L.3
Bhalla, K.4
O'Brien, S.5
Wassmann, B.6
Tanaka, C.7
Manley, P.8
Rae, P.9
Mietlowski, W.10
Bochinski, K.11
Hochhaus, A.12
Griffin, J.D.13
Hoelzer, D.14
Albitar, M.15
Dugan, M.16
Cortes, J.17
Alland, L.18
Ottmann, O.G.19
-
21
-
-
57749174353
-
Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ALL) [abstract]
-
Tanaka C., Smith T., Kantarjian H., et al. Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ALL) [abstract]. J Clin Oncol. 2006 ; 24: 18S.
-
(2006)
J Clin Oncol
, vol.24
-
-
Tanaka, C.1
Smith, T.2
Kantarjian, H.3
-
22
-
-
0037427972
-
The superfamily of organic anion transporting polypeptides
-
Hagenbuch B., Meier PJ The superfamily of organic anion transporting polypeptides. Biochem Biophys Acta. 2003 ; 1609: 1-18.
-
(2003)
Biochem Biophys Acta
, vol.1609
, pp. 1-18
-
-
Hagenbuch, B.1
Meier, P.J.2
|